




PHARMACEUTICAL 2019

NovaBay Pharmaceuticals Inc.
Rank 240 of 363





RealRate

PHARMACEUTICAL 2019

NovaBay Pharmaceuticals Inc. Rank 240 of 363



The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 134% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 142% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 8.1% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	8,608
Cost of Goods Sold	1,503
Intangible Assets	0
Liabilities, Current	3,847
Liabilities, Non-Current	198
Other Assets	552
Other Compr. Net Income	0
Other Expenses	11,482
Other Liabilities	362
Other Net Income	19
Other Revenues	12,508
Property and Equipment	201
Research and Development	259
Selling, General and Administrative Expense	5,828

Output Variable	Value in 1000 USD
Assets	9,361
Liabilities	4,407
Expenses	19,072
Revenues	12,508
Stockholders Equity	4,954
Net Income	-6,545
Comprehensive Net Income	-6,545
Economic Capital Ratio	29%